1 T cell responses by their capacity to cross-present exogenous antigens via the major histocompatibility complex class I pathway. The myeloid class I IgG receptor, FccRI (CD64), is expressed on DC, and in vivo targeting of antigens to FccRI induces strong humoral and cellular immune responses. We studied the capacity of human FccRI (hFccRI) to facilitate DC-mediated cross presentation and T cell activation, and assessed the effect of CpG oligodeoxynucleotides on this process. We generated hFccRI expressing immature DC from hFccRI transgenic and immature DC from non-transgenic mice. Antigens were targeted to Fcc receptors as ovalbumin immune complexes, or selectively to hFccRI via ovalbumin-CD64 mAb fusion proteins. Coincubation of immature DC with CpG ODN led to markedly increased MHC class I presentation of FccR-targeted antigens. When OVA was selectively targeted to hFccRI, few differences were observed between Tg and NTg DC. However, upon co-incubation with CpG ODN, hFccRI-triggered cross presentation was enhanced. These results document the capacity of hFccRI on DC to trigger cross presentation via MHC class I upon co-culture with CpG ODN.
Introduction
Dendritic cells are professional antigen-presenting cells, with a unique capacity to induce primary immune responses. Tissue resident immature DC exert high endocytic and phagocytic activities that are mitigated upon maturation in favor of an enhanced capacity to present antigens (1) . Dendritic cellmediated antigen presentation initiates specific immune responses involving both CD4 + and CD8 + T cell activation. In general, exogenous antigens are presented on MHC class II molecules, and endogenous antigens via the MHC class I pathway. However, cross presentation by DC of exogenous antigens on class I molecules can represent a potent pathway to elicit primary CD8 + T cell responses (2, 3) . Cross presentation is a rather inefficient process, as fluid phase internalization only results in class I restricted presentation at high concentrations of antigen (4, 5) . FccR-mediated uptake of complexed antigens can markedly enhance the efficiency of cross presentation (6) .
The human receptor with high affinity for IgG, hFccRI (CD64), is exclusively expressed on cells of the myeloid lineage including monocytes, macrophages, granulocytes (upon cytokine induction) and DC (7). hFccRI is unique among leukocyte FccR, because of its structure, limited cell distribution and function. This receptor has three Ig-like extracellular domains that bind monomeric IgG with high affinity, in contrast to the other FccR. hFccRI on antigenpresenting cells can facilitate antigen-specific CD4 + T cell responses by antigen-presenting cells, and effectively triggers anti-tumor vaccine responses (8) (9) (10) (11) . Because of these features and the fact that hFccRI-targeted antigens co-localize with MHC class I molecules in subcellular organelles (12) , we postulated hFccRI to be a candidate for facilitation of DC cross presentation.
Bacterial DNA has direct and indirect immunostimulatory effects on immune cells due to the presence of unmethylated CpG dinucleotide motifs that bind to Toll-like receptor 9 (TLR9), which is a pattern recognition receptor expressed by a subset of cells including DC. These unmethylated CpG dinucleotides are present in the expected frequency in bacterial DNA but methylated and suppressed in vertebrate DNA (13, 14) . Synthetic immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG ODN) can interact with TLR9, activate immune cells, and induce the production of various cytokines (15) . In addition, CpG ODN exhibit the capacity to induce growth, activation and maturation of DC (16) (17) (18) .
To study the capacity of hFccRI to facilitate DC-mediated cross presentation of targeted exogenous antigen, we used bone marrow-derived DC (BMDC) from unique hFccRI transgenic mice (8) . Ovalbumin (OVA) was targeted to FccRI by OVA-IgGaOVA immune complexes, by an OVA-CD64 antibody fusion protein, or by an OVA-CD64 chemically linked protein. These latter two constructs selectively target OVA to an epitope on hFccRI, located outside the IgG-binding domain (19) . Our results document hFccRI to efficiently facilitate DCmediated cross presentation, upon incubation of DC with CpG ODN.
Methods

Mice
Human FccRI Tg animals (8) crossed with C57Bl6 (F1), or Balb/c mice (F12) were bred and maintained at the Transgenic Mouse Facility of the Central Animal Laboratory, Utrecht University. C57Bl/6 and Balb/c mice were obtained from Harlan (Horst, The Netherlands). 8-12-week-old human CD64-expressing animals were used in the experiments, as well as their NTg littermates. The Utrecht University animal ethics committee approved all experiments.
Cell lines
The RF33 cell line, expressing a TCR recognizing the H-2 brestricted OVA epitope SIINFEKL (20) , and the OVA-specific D011.10 cell line, that recognizes the OVA peptide in an Ia d restricted way (21) , were cultured in RPMI 1640 medium (Gibco BRL, Life Technologies, Paisley, UK), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Fetalclone I, Hyclone, Logan, UT), 50 IU/ml penicillin (Gibco BRL) and 50 lg/ml streptomycin (Gibco BRL). The interleukin 2 (IL-2) dependent CTLL-2 cell line (22) was propagated in RPMI 1640 medium, with 10% FBS, 50 IU/ml penicillin, 50 lg/ml streptomycin and 100 U/ml IL-2 (Immunokine, Boehringer Ingelheim, Alkmaar, The Netherlands). 
Antibodies
CD80 (clone 1G10
)
Antigens
The immunodominant peptide of OVA, SIINFEKL (OVA 257-264), was obtained from Isogen (Maarssen, The Netherlands). Ovalbumin complexes were generated by incubation of 40 lg/ml chicken egg OVA (Sigma, St Louis, MO) with 80 lg/ml rabbit IgG anti-OVA (Sigma) for 20 min at 37°C. 223OVA conjugates were prepared using N-succinimidyl Sacetylthioactetate (SATA) (Pierce, Rockford, IL) and SPDP (Pierce) as chemical cross-linkers (25) . 22-OVA fusion protein was generated by standard methods. Briefly, the VH and VL encoding regions of H22 (19) were used to generate the 22sFv vector [kindly provided by Dr Joel Goldstein (Medarex, Annandale, NH)]. cDNA encoding the OVA sequence was inserted into the 22sFv vector, producing a 22sFv and OVA gene fusion (22-OVA). 22-OVA recombinant baculovirus was generated using the BD Baculogold Transfection kit as recommended by the manufacturer. Trichopluscia Ni (Hi-5) insect cells were infected with high titre baculovirus encoding 22-OVA at a multiplicity of infection of 10. After 4 days, supernatant was collected, concentrated and purified. Purified protein constructs were run out on 6% acrylamide gels and stained with Coomassie brilliant blue to test for purity. All protein constructs were tested for lipopolysaccharide (LPS) contamination by the Limulus Amebocyte Lysate QCL-1000 assay kit (BioWhittaker, Walkersville, MD).
CpG ODN
Synthetic ODN were provided by Coley Pharmaceutical Corporation (Wellesly, MA). CpG ODN 1826 with the following sequence was used: TCCATGACGTTCCTGACGTT. In addition, CpG ODN were tested and proved to contain <12.5 ng/ mg of lipopolysaccharides levels by Limulus Amebocyte Lysate QCL-1000 assay kit.
Generation of DC
Bone-marrow derived DC (BMDC) were obtained as described by Inaba et al. (26) . Briefly, bone marrow was flushed from mouse femurs, erythrocytes were lysed and cells were grown at 1 3 10 6 /ml in filtered RPMI + (RPMI 1640 medium with 10% FBS, 50 IU/ml penicillin and 50 lg/ml streptomycin) in the presence of either 10 ng/ml granulocyte macrophage colonystimulating factor (GM-CSF; Immunex, Seattle, WA) or 10 ng/ ml GM-CSF + 50 ng/ml tumor necrosis factor alpha (TNF-a; Hycult, Uden, The Netherlands). Non-adherent cells were replated on day 1, and non-adherent cells were removed on days 2 and 4 from the cultures, with concomitant refreshment of culture media. Non-adherent and loosely adherent DC were harvested on days 7, 8 or 9.
Flow cytometric analyses
Day 7 DC (DC7) (1 3 10 5 ), day 8 DC cultured for 24 h with 10 lg/ml CpG ODN, and DC7 which were cultured for 48 h with 1 lg/ml LPS (Sigma), were blocked with 5% heat-inactivated mouse serum for 30 min at room temperature (RT). Cells were washed with FACS buffer [phosphate-buffered saline (PBS), 0.1% azide, 1% bovine serum albumin (BSA)] and incubated with different mAb for 20 min at RT. Cells were washed again and, if required, incubated with secondary antibodies. Cells were analyzed by flow cytometry using a FACSCalibur (BD Biosciences). Unstained cells, isotype controls and secondary (fluorochrome-labeled) antibodies were used as negative controls. MHC class I antigen presentation DC7 (1 3 10 5 ) were washed twice in RPMI + medium and resuspended in 150 ll RPMI + /well. DC were incubated with OVA alone (100 ng/ml), OVA-IgGaOVA complexes, 22-OVA or 223OVA, either with or without 10 lg/ml CpG ODN 1826 for 24 h at 37°C. The SIINFEKL peptide (0.29 mg/ml) served as a positive control. OVA-IgGaOVA complexes were generated by incubating DC with 100 ng/ml of OVA and varying concentrations of rabbit anti-OVA. After 24 h, cells were washed once with RPMI ÿ medium (RPMI 1640 medium only) and fixed using 1.5% paraformaldehyde for 20 min at RT. Cells were washed once in RPMI ÿ medium and quenched with 50 mM NH 4 Cl for 60 min at RT. This was followed by washing trice in RPMI ÿ medium and resuspension in 100 ll RPMI + /well. RF33 cells, 1 3 10 5 , were added in a volume of 50 ll, and incubated for 36 h at 37°C. One hundred microliters of supernatant were harvested from each well. The presence of IL-2 released by RF33 cells in culture supernatants was determined as above.
MHC class II antigen presentation
Statistical analysis
Differences between groups were analyzed by one-way ANOVA. A P-value <0.05 was considered significant.
Results
Effect of culture conditions on DC phenotype and expression of hFccRI
To study hFccRI on dendritic cells as target molecule for vaccine development, we assessed bone marrow-derived DC. To obtain DC with hFccRI expression, we cultured bone marrow from hFccRI-transgenic mice for 7 days in the presence of GM-CSF or GM-CSF/TNFa. The well-described GM-CSF/IL-4 culture method was not used, as IL-4 downregulates hFccRI expression on myeloid cells (8, 27) . BMDC cultured for 7 days (DC7) with GM-CSF showed a clear immature DC phenotype, indicated by expression of CD11c, DEC-205, high expression of Fcc receptors and low expression levels of costimulatory and MHC molecules (Fig. 1 ). DC cultured with GM-CSF/TNFa demonstrated a higher expression of CD86 and MHCII, representing a more mature phenotype (data not shown). In addition, DC7 expressed F4/80, and no B or Tcell markers (data not shown). Expression of GR-1 was consistently found on DC upon 7 days of culture (Fig. 1) , which was down modulated upon full maturation (data not shown). The presence of the hFccRI did not cause any change in marker expression, as NTg and Tg DC exhibited similar expression patterns for all markers tested (data not shown).
Human FccRI is expressed on cells of the myeloid lineage, including monocytes, macrophages and dendritic cells. To document that hFccRI was present on dendritic cells in our cultures, we triple-stained for CD11b, CD11c and hFccRI. Both GM-CSF (Fig. 2) and GM-CSF/TNFa (data not shown) CD11b + CD11c + DC7 expressed hFccRI, albeit hFccRI expression levels were lower on GM-CSF/TNFa DC7. This is consistent with earlier observations that DC maturation coincides with down regulation of hFccRI expression (28) .
MHC class II antigen presentation is equivalent in NTg and hFccRI Tg DC Next, we measured MHC class II dependent antigen presentation by DC derived from NTg and Tg DC, to exclude differences in functionality of Tg DC. DC were incubated with excess OVA (400 lg/ml), to assess its capacity to internalize antigen via fluid phase antigen uptake, and subsequent processing. To study FccR-mediated uptake and processing, DC were incubated with 300 ng/ml OVA-IgGaOVA immune complexes. As read out we used OVA-specific MHC class II restricted D011.10 T cells. hFccRI Tg and NTg DC7 exhibited similar capacity to pinocytoze and process fluid phase OVA (Fig. 3) . OVA-immune complexes triggered T cell proliferation at 100-fold lower concentrations, confirming that receptormediated endocytosis and processing is more efficient. Importantly, hFccRI Tg and NTg DC were similar in their ability to activate class II restricted T cells (Fig. 3) . This demonstrated class II antigen presentation, and subsequent T cell activation, not to be influenced by the transgenic hFccRI.
Effect of CpG ODN on DC cell surface marker expression
CpG ODN can exhibit direct effects on DC differentiation and maturation, and enhance cross presentation of MHC class I restricted peptides and fluid phase-internalized antigens (17) . Before studying the effect of CpG ODN on FccR-triggered antigen presentation, we analyzed the effect of CpG ODN on cell surface marker expression of GM-CSF and GM-CSF/TNFa immature DC. DC7 were co-cultured with CpG ODN for 24 h, and marker expression levels examined. CpG ODN clearly activated DC7, as reflected by upregulation of the level of costimulatory and MHC class II molecules, and down regulation of FcR, such as human FccRI, and mouse FccRII/FccRIII (Fig. 4) .
CpG ODN enhance cross presentation of FccR-targeted immune complexes
In order to study the effect of CpG ODN on FccR-triggered cross presentation, we established whether the presence of Fig. 2 . Expression of hFccRI on dendritic cells. Human hFccRI Tg and NTg DC were cultured for 7 days in the presence of GM-CSF and GM-CSF/TNFa. Triple staining for CD11b, CD11c and hFccRI was performed and analyzed by flow cytometry. Expression of hFccRI by the CD11b/CD11c double positive cell population is depicted, and one representative experiment out of four is shown. Fig. 3 . MHC class II antigen-presenting capacity of DC. Human FccRI Tg and NTg DC, cultured for 7 days in the presence of either GM-CSF or GM-CSF/TNFa, were incubated with excess OVA (400 lg/ml) as fluid phase control, with OVA-IgGaOVA immune complexes (300 ng/ ml), or with OVA (300 ng/ml), and OVA-specific MHC class II restricted DO11.10 T cells for 24 h at 37°C. IL-2 production by T cells was quantified by CTLL-2 proliferation assays. Data represent means of duplicate determinations in one representative experiment out of four, in which the specific signal minus background is depicted. Statistic significant differences in antigen presentation of immune complexes vs ovalbumin by NTg or Tg DC are depicted in the figure. hFccRI affected the ability of DC7 to activate class I restricted T cells. DC7 from hFccRI Tg and NTg mice, cultured with GM-CSF and GM-CSF/TNFa, were incubated with the class I restricted OVA peptide SIINFEKL with or without CpG ODN. After 24 h, DC were fixed and MHC class I restricted OVA-specific RF33 Tcells were added for 36 h. In the absence of CpG ODN, both types of DC showed similar ability to activate class I restricted T cells. Additional stimulation with CpG ODN further enhanced DC ability to activate class I restricted T cells (Fig. 5A) .
Subsequently, hFccRI Tg and NTg DC were incubated with OVA immune complexes at varying concentrations. Immune complex-triggered cross presentation was higher in hFccRI Tg than in NTg DC (Fig. 5B) , reaching a statistically significant difference in GM-CSF/TNFa DC, indicative of an effect mediated by the transgenic hFccRI. Stimulation with CpG ODN further increased cross presentation (Fig. 5B ). CpG ODN clearly had an additive effect on hFccRI-mediated cross presentation, as antigen presentation in the Tg + CpG group was enhanced to a higher extend than antigen presentation by DC of the NTg + CpG group.
CpG ODN enhance cross presentation of human FccRItargeted antigens
The capacity of hFccRI to induce DC-mediated cross presentation of OVA and the effect of CpG ODN stimulation on this process was examined next. To target OVA to hFccRI, two approaches were followed. Firstly, an scFv fragment of mAb H22 to hFccRI was genetically linked to OVA (22-OVA). As this construct only contains 22 scFv, it is not expected to cause massive receptor crosslinking (10, 29) . Secondly, OVA was chemically cross-linked to whole IgG of monoclonal antibody H22 (223OVA), which results in a molecule targeting OVA to hFccRI that cross-links the receptor (19) . DC7 from hFccRI Tg and NTg mice, cultured with GM-CSF or GM-CSF/TNFa, were incubated with either 22-OVA, or 223OVA, in the presence or absence of CpG ODN for 24 h. DC were fixed, and subsequently incubated with MHC class I restricted OVAspecific RF33 T cells for 36 h. In the absence of CpG ODN, very limited hFccRI-triggered cross presentation of OVA by DC was detected (Fig. 6 ). When CpG ODN were added, an increase in hFccRI-mediated antigen presentation was observed, as reflected by higher antigen presentation of CpG ODN-stimulated hFccRI Tg DC7, compared to NTg DC7 (Fig. 6) . This difference reached statistical significance using a concentration of 1 lg/ml for 22-OVA, and 5 lg/ml for 223OVA. Ovalbumin alone used at concentrations of either 1 or 5 lg/ml was applied as control, inducing an average [ 3 H]thymidine incorporation of 500 c.p.m. Ovalbumin coincubated with CpG reached an average incorporation of 1000 c.p.m. The fact that both 22-OVA and 223OVA triggered cross presentation indicated cross-linking of hFccRI not to be crucial for this process.
Discussion
To study the role of hFccRI as a target molecule on DC, we used a unique and well-defined FccRI Tg mouse model (8, 10) . We cultured bone marrow from hFccRI transgenic mice with GM-CSF or GM-CSF/TNFa, to generate BMDC which express human FccRI in addition to mouse FccR. Consistent with earlier work (1, 26, 30) , these protocols yielded immature DC.
In this study, we focused on the effect of CpG ODN on FccRmediated cross presentation. Our results confirmed that CpG ODN enhance expression of costimulatory molecules, induce down modulation of FccR, and augment MHC class I restricted peptide presentation. Importantly, FccR-mediated cross presentation of OVA immune complexes was up-regulated 2-to 4-fold upon CpG ODN activation, despite the fact that CpG ODN down regulated FccR expression. This is consistent with earlier data in the literature, documenting CpG ODN to act as adjuvants for MHC class I restricted epitopes (18) , and CpG ODN treatment of peptide-or protein-pulsed DC to enhance activation of class I restricted T cells (31, 32) . However, these data show for the first time that CpG activation of DC enhances FccR-mediated antigen presentation. hFccRI is the high affinity receptor for monomeric IgG, and is, therefore, likely occupied with serum IgG in vivo (33) . To study potential in vivo dendritic cell based strategies, we targeted hFccRI outside its IgG ligand-binding domain using monoclonal antibody H22. By using genetically linked 22-OVA, or chemically-linked 223OVA, we selectively targeted OVA to hFccRI, without interference of murine FccR. Human FccRI targeting on Tg DC resulted in no cross presentation. Incubation of DC with hFccRI-targeted antigens and CpG ODN clearly induced cross presentation of antigen-derived peptides on MHC class I molecules, both when OVA was targeted via 22-OVA and 223OVA. Binding of 223OVA to Tg DC induces crosslinking, whereas 22-OVA is not likely to induce massive crosslinking and this difference in type of activation of the receptor might lead to different intracellular trafficking and presentation of OVA. 22-OVA antigen uptake by NTg DC was apparently influenced by CpG, in that more 22-OVA was non-specifically (without interacting with the human FccRI) taken up and presented upon CpG coincubation. Differences observed in NTg DC between 22-OVA and 223OVA might be attributable to the size of the molecule, as 22-OVA is smaller than 223OVA and more efficient non-FcR-mediated uptake might be envisaged. Data in this paper show that antigen presentation by the human high affinity receptor for IgG on DC can be enhanced by CpG activation.
Our data may underlie the well-documented anti-tumor and vaccine responses seen upon targeting hFccRI in hFccRItransgenic mouse models (11, 34, 35) . Consistent with the present data, FccRI-targeted antigens can co-localize with MHC class I molecules in human monocytic U937 cells (12) , and were presented on MHC class I in the human THP-1 myeloid cell line (36) .
The mechanism by which hFccRI directs antigens to MHC class I processing pathways has not been elucidated. Cross presentation upon targeting antigens to FcR by liposomes (37) , or by immune complexes (6, 38) , was shown to require proteosomal degradation and a functional TAP. This suggests an escape of antigens from phagosome to cytosol to be involved in FccRI-mediated cross presentation. In addition, recent publications indicate an ER-phagosome fusion compartment to be an important cell organelle for cross presentation (39) (40) (41) . This represents an additional route for loading of exogenous antigen-derived peptide on MHC class I molecules, which might be of importance for FccRI-mediated cross presentation. Human FccRI exists as a heterooligomeric receptor complex, with a ligand binding a-chain and a promiscuous FcR c-chain homodimer (7,33). We previously documented hFccRI to be unique within the leukocyte FccR family, in that the a-chain exhibits the capacity to route endocytozed antigens to intracellular compartments positive for MHC class II (10) . Whether the FccRI a-chain is also involved in routing antigens to the MHC class I cross presenting pathway is currently under active investigation.
Dendritic cells express different subsets of Toll-like receptors, which enables them to react to diverse pathogens. TLR9 has been recognized as a receptor for CpG DNA (42) . Several studies indicate that CpG are internalized and bind to TLR9, located within the endosome (43) (44) (45) . Binding of TLR9 triggers cell signaling pathways including the mitogen activated protein kinases (MAPKs) and NF-jB (46) . In DC this results in maturation, Th1-driven cytokine production and prolonged survival (14, 16, 17) . In the present study we demonstrate that CpG ODN can increase cross presentation of antigens selectively targeted to hFccRI. Increased receptor-mediated uptake of antigens, improved hFccRI-triggered cross presentation by transiently augmenting antigen processing, increased expression of co-stimulatory molecules or enhanced half-life of peptide-MHC complexes are putative mechanisms underlying the influence of CpG on antigen presentation (47) .
In mice, TLR9 is expressed in both myeloid and plasmacytoid DC (pDC), whereas in humans expression is only apparent in pDC (48, 49) . In humans, hFccRI is only expressed on myeloid DC, and whether combining CpG ODN and hFccRI as target molecule on myeloid DC leads to efficient vaccination in humans remains to be shown. CpG-triggered IFN-a production by pDC, and subsequent activation of (hFccRIexpressing) myeloid DC may represent an attractive concept for immunotherapy (50, 51) .
Due to the fact that DC represent the most potent initiators of immune responses (1, 52) , and are capable of funneling exogenous antigens into the MHC class I restricted antigen presentation pathway (5,53), they may represent tools for the development of future therapeutic concepts. Carefully designed combination strategies of CpG ODN and hFccRItargeting, which have shown promising results in murine models (54) , may have potential to further improve DC-based vaccines.
